Jiangsu Kanion Pharmaceutical Co.,Ltd.

XSSC:600557 Stock Report

Market Cap: CN¥8.0b

Jiangsu Kanion PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Jiangsu Kanion PharmaceuticalLtd has been growing earnings at an average annual rate of 7.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.1% per year. Jiangsu Kanion PharmaceuticalLtd's return on equity is 10.3%, and it has net margins of 12.1%.

Key information

7.5%

Earnings growth rate

8.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.1%
Return on equity10.3%
Net Margin12.1%
Next Earnings Update30 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jiangsu Kanion PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600557 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,4815442,120728
30 Jun 244,5745262,149747
31 Mar 244,8745432,268787
31 Dec 234,8685372,284772
30 Sep 234,7215032,286679
30 Jun 234,8074992,313692
31 Mar 234,6254662,221650
31 Dec 224,3514342,060606
30 Sep 224,1903951,965600
30 Jun 223,9773721,887560
31 Mar 223,8653471,831540
31 Dec 213,6493211,745499
30 Sep 213,3442821,598430
30 Jun 213,2542781,572403
31 Mar 213,0752671,503399
31 Dec 203,0322631,457380
30 Sep 203,4713211,714376
30 Jun 203,8504091,955370
31 Mar 204,3054792,219422
31 Dec 194,5665072,457443
30 Sep 194,4354802,433416
30 Jun 194,2424552,314378
31 Mar 194,0084282,172313
31 Dec 183,8254142,041290
30 Sep 183,6193811,937261
30 Jun 183,4573841,648416
31 Mar 183,4013821,708318
31 Dec 173,2753741,700237
30 Sep 173,1363821,597202
30 Jun 173,1613741,8690
31 Mar 173,0713781,8090
31 Dec 163,0003741,7480
30 Sep 162,9603671,7290
30 Jun 162,8963631,6660
31 Mar 162,8613631,6230
31 Dec 152,8203621,6010
30 Sep 152,8153581,6060
30 Jun 152,7553491,5550
31 Mar 152,6313291,4740
31 Dec 142,5633201,4360
30 Sep 142,4773241,3570
30 Jun 142,4183231,3420
31 Mar 142,3383111,3110
31 Dec 132,2302971,2600

Quality Earnings: 600557 has a large one-off gain of CN¥99.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 600557's current net profit margins (12.1%) are higher than last year (10.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600557's earnings have grown by 7.5% per year over the past 5 years.

Accelerating Growth: 600557's earnings growth over the past year (8.3%) exceeds its 5-year average (7.5% per year).

Earnings vs Industry: 600557 earnings growth over the past year (8.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 600557's Return on Equity (10.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 00:49
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Kanion Pharmaceutical Co.,Ltd. is covered by 30 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
Changming HeBOCI Research Ltd.
Feifei MaBohai Securities Co., Ltd.